ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Interview

Eisai CEO sets sights on Asia with Alzheimer's drug approved in US

Haruo Naito sees 'enormous' market in China, Japan and elsewhere

Eisai CEO Haruo Naito says a newly approved therapeutic Alzheimer's disease drug co-developed with U.S.-based Biogen will become a "substantial blockbuster" in an interview with Nikkei on June 8. (Photo by Tomoko Wakasugi)

TOKYO - Japanese drugmaker Eisai is betting on Asia to boost sales of a newly approved therapeutic Alzheimer's disease drug co-developed with U.S.-based Biogen, as the aging region faces a rapid increase in dementia patients.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more